Bacillus subtilis JZH 9 capable of inhibiting escherichia coli and application
By inhibiting Escherichia coli with Bacillus subtilis JZH 9, the problem of drug resistance in avian colibacillosis was solved, the growth performance and intestinal health of chicks were improved, and a protective effect was achieved for chicks.
Patent Information
- Application Number
- CN202411164634.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
In the current technology, the treatment of avian colibacillosis relies on antibiotics, which leads to drug resistance. There is a lack of effective antibiotic alternatives, which affects poultry health and causes economic losses to the poultry industry.
A strain of Bacillus subtilis JZH 9 is provided, which has the ability to inhibit Escherichia coli, can colonize in the gastrointestinal environment, increase intestinal villus height and villus-crypto ratio, improve intestinal structure, reduce intestinal Escherichia coli content, and reduce colonization.
Bacillus subtilis JZH 9 can prevent diarrhea in chicks, improve growth performance, improve intestinal health, reduce the content of Escherichia coli in the intestine, reduce colonization, and provide protection for the body.
Smart Images

Figure CN119020216A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a strain of Bacillus subtilis JZH 9 capable of inhibiting Escherichia coli and an application thereof. Background Art
[0002] Avian colibacillosis is a common disease caused by Escherichia coli, which can cause a variety of diseases in poultry, including acute septic salpingitis, air sacitis, pericarditis, enteritis, and yolk sac inflammation. Avian E. coli can cause local or systemic bacterial infection in poultry, which can lead to severe diarrhea in chicks, reduce growth performance, meat production, and egg production, and in severe cases, lead to death. Avian colibacillosis is common in all breeds and age stages, with an incidence rate of 11%-69% and a mortality rate of 3.2%-72.9%. It seriously affects the health of poultry and the development of the breeding industry, causing huge economic losses to the breeding industry. At present, most of the drugs used in clinical treatment of avian colibacillosis use antibiotics, and the main drugs are amoxicillin, ceftiofur, streptomycin and tetracycline. However, the abuse of antibiotics has made E. coli resistant to different types of antibiotics, resulting in poor treatment effects. With the advent of the era of comprehensive antibiotic prohibition, the demand for antibiotic substitutes is becoming more and more urgent, and probiotics have received widespread attention.
[0003] In view of the problem of drug resistance in the current clinical drugs for avian Escherichia coli disease, the present invention provides a strain of Bacillus subtilis JZH 9 that can inhibit Escherichia coli, which can prevent diarrhea in chicks caused by Escherichia coli O78; it has a certain tolerance to bile salts, and when the pH is 3-4, the survival rate reaches 38.56%-63.38%, so that it can colonize in the intestine through the gastrointestinal environment. Bacillus subtilis JZH 9 can increase the height of intestinal villi and the villus-crypt ratio, improve the intestinal structure, and can reduce the content of intestinal Escherichia coli, reduce the colonization of Escherichia coli O78 in the intestine, thereby achieving a protective effect on the body. Summary of the invention
[0004] To achieve the above object, the main contents of the present invention are as follows:
[0005] The primary purpose of the present invention is to provide a strain of Bacillus subtilis JZH 9 that can inhibit Escherichia coli. The Bacillus subtilis JZH 9 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 10, 2024, with a deposit number of CGMCC No.30580.
[0006] The second object of the present invention is to provide the use of the Bacillus subtilis JZH 9 in inhibiting the growth of Escherichia coli.
[0007] The third object of the present invention is to provide the use of the Bacillus subtilis JZH 9 in promoting the growth of chicks.
[0008] The fourth object of the present invention is to provide the use of the Bacillus subtilis JZH 9 in improving the villus height and villus-to-crypt ratio of the duodenum.
[0009] The fifth object of the present invention is to provide the use of the Bacillus subtilis JZH 9 in improving intestinal structure and enhancing intestinal barrier function.
[0010] The sixth object of the present invention is to provide the use of the Bacillus subtilis JZH 9 in reducing the colonization of Escherichia coli in the intestine.
[0011] The seventh object of the present invention is to provide a bacterial agent, which is prepared by fermenting the Bacillus subtilis JZH 9 strain.
[0012] The eighth object of the present invention is to provide a feed additive, characterized in that the feed additive includes the bacterial agent and other acceptable nutrients in the feed.
[0013] Preferably, the other nutrients include at least one of probiotics, minerals and vitamins.
[0014] The beneficial effects of the present invention are as follows: the present invention provides a strain of Bacillus subtilis JZH 9 capable of inhibiting Escherichia coli. The Bacillus subtilis JZH 9 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 10, 2024, with a deposit number of CGMCC No. 30580. The Bacillus subtilis JZH 9 can prevent diarrhea in chicks caused by Escherichia coli O78; it has a certain tolerance to bile salts, and at a pH of 3-4, the survival rate reaches 38.56%-63.38%, so that it can colonize in the intestine through the gastrointestinal environment. Bacillus subtilis JZH 9 can increase the villus height and villus-cryptographic ratio of intestinal tissue, improve the intestinal structure, and can reduce the content of intestinal Escherichia coli, reduce the colonization of Escherichia coli O78 in the intestine, thereby achieving a protective effect on the body. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Phylogenetic tree of isolated strain Bacillus subtilis JZH 9
[0016] Figure 2 Acid tolerance of Bacillus subtilis
[0017] Figure 3 Bile salt tolerance of Bacillus subtilis
[0018] Figure 4Hemolytic activity of Bacillus subtilis
[0019] Figure 5 Note: CON: control group; LBS: low-dose Bacillus subtilis control group (1×10 9 CFU / mL; MBS: medium-dose Bacillus subtilis control group (1×10 10 CFU / mL; HBS: high-dose Bacillus subtilis control group (1×10 11 CFU / mL); Model: Model group (Escherichia coli O78: 4.5×10 12 CFU / mL; LBS+E.coli: low-dose Bacillus subtilis group (Bacillus subtilis (1×10 9 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL)); MBS+E.coli: medium-dose Bacillus subtilis group (Bacillus subtilis (1×10 10 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL)); HBS+E.coli: high-dose Bacillus subtilis group (Bacillus subtilis (1×10 11 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL)).
[0020] Figure 6 Effect of Bacillus subtilis on the content of Escherichia coli O78 in the jejunum of chickens Note: CON: control group; Model: model group (Escherichia coli O78: 4.5×10 12 CFU / mL; LBS+E.coli: low-dose Bacillus subtilis group (Bacillus subtilis (1×10 9 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL)); MBS+E.coli: medium-dose Bacillus subtilis group (Bacillus subtilis (1×10 10 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL)); HBS+E.coli: high-dose Bacillus subtilis group (Bacillus subtilis (1×10 11 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL) DETAILED DESCRIPTION
[0021] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0022] In the following examples, unless otherwise specified, the methods used are all conventional methods, and the reagents used are all available from commercial sources.
[0023] In the following examples, Bacillus subtilis JZH 9 is abbreviated as Bacillus subtilis JZH 9, and Bacillus subtilis JZH 9 and Bacillus subtilis JZH 9 have the same meaning.
[0024] Example 1. Screening and application of Bacillus subtilis JZH 9
[0025] 1. Materials and Reagents
[0026] Screening for Bacillus subtilis:
[0027] Fresh feces of healthy laying hens; LB broth (Haibo Biotechnology Co., Ltd., China), agar powder (Haibo Biotechnology Co., Ltd., China), Columbia blood agar medium (Nanjing Quanlong Biotechnology Co., Ltd., China).
[0028] Resistance test:
[0029] LB broth, agar powder, 1 mol / L HCl, 1 mol / L NaOH, 0.9% sodium hydroxide solution, sodium taurocholate (Sangon Biotechnology Co., Ltd., China), pepsin (Solarbio, China), trypsin (Solarbio, China); culture dish, UV-visible spectrophotometer (Shanghai Jinghua Technology Co., Ltd., China).
[0030] 2. Test methods
[0031] 2.1 Screening of Bacillus subtilis
[0032] Preparation of culture medium: LB broth liquid culture medium: weigh 25 g LB broth and dissolve it in 1 L distilled water, and press high pressure at 121°C for 15 min; LB agar solid culture medium: weigh 25 g LB broth and 15 g agar powder and dissolve them in 1 L distilled water, and press high pressure at 121°C for 15 min.
[0033] Collect fresh feces from healthy laying hens, suspend them with PBS, spread them on the prepared LB agar solid medium, and culture them at 37℃ for 24h. After the culture is completed, pick a single colony suspected of Bacillus subtilis and continue to purify it by streaking for 3-4 generations. Pick the purified single colony and amplify and activate it in LB liquid medium, and culture it at 37℃ for 12h. Take the activated bacterial liquid, extract its DNA, and perform 16SrRNA sequencing. The sequencing results are compared on NCBI to determine the type of strain.
[0034] 2.2 In vitro screening of Bacillus subtilis that inhibit Escherichia coli
[0035] Bacillus subtilis and Escherichia coli O78 were revived and activated, and the single colony of the third activation was picked into liquid culture medium and cultured at 37℃ for OD 600 The antibacterial activity was determined by the Oxford cup method. Escherichia coli liquid was evenly coated on the surface of the solid culture medium. An Oxford cup was placed on the surface of the culture medium. 100 μL of Bacillus subtilis liquid was added to the Oxford cup. An equal volume of LB liquid culture medium was added to the Oxford cup as a control. The culture was cultured at 37°C for 24 hours, and the diameter of the inhibition zone was measured.
[0036] 2.3 Resistance test
[0037] Acid resistance test:
[0038] The pH of LB liquid culture medium was adjusted to 2.0, 3.0, 4.0, and 5.0 with 1 mol / L HCl. The culture medium without pH adjustment was used as the control. After high-pressure sterilization at 121°C, 1% bacterial solution was added and cultured at 37°C for 2 hours. Samples were taken for plate live bacteria count and the survival rate was calculated.
[0039] Bacterial survival rate % = number of viable bacteria in the test group / number of viable bacteria in the control group × 100%
[0040] Bile salt tolerance test:
[0041] LB liquid medium was added with sodium taurocholate to prepare liquid medium with bile salt concentrations of 0.00% (control), 0.15%, 0.20%, 0.25%, 0.30%, 0.35%, and 0.40%, respectively. After high-pressure sterilization at 121°C, 1% bacterial solution was added to each medium and cultured in a 37°C incubator for 12 hours. The OD value of the bacterial solution was measured. 600 The absorbance at .
[0042] Artificial gastric fluid resistance test:
[0043] Add 0.1 mol / L HCl solution to 100 mL of normal saline to adjust pH to 3, and add 0.3 g of pepsin to fully dissolve after autoclaving. Centrifuge the cultured Bacillus subtilis, discard the supernatant, resuspend in an equal volume of artificial gastric juice and immediately perform plate counts. Perform a second plate count after culturing at 37°C for 2 hours to calculate the survival rate. The culture not treated with artificial gastric juice was used as a control.
[0044] Bacterial survival rate % = number of viable bacteria in the test group / number of viable bacteria in the control group × 100%
[0045] Artificial intestinal fluid resistance test:
[0046] Add 0.1 mol / L NaOH solution to 100 mL of normal saline to adjust pH to 8, add 0.1 g of trypsin after autoclaving, and then add 0.9 g of sodium taurocholate to fully dissolve. Centrifuge the cultured Bacillus subtilis, discard the supernatant, resuspend in an equal volume of artificial intestinal fluid and immediately plate count, culture at 37°C for 2 hours, plate count for the second time, calculate the survival rate, and use the control without artificial intestinal fluid treatment.
[0047] Bacterial survival rate % = number of viable bacteria in the test group / number of viable bacteria in the control group × 100%
[0048] 2.4 Hemolytic assay
[0049] The three-zone streak method was used. The strain to be tested was inoculated onto the blood plate using an inoculation loop and cultured at 37°C for 24 hours. The hemolysis ring was observed and the type of hemolysis was determined. If no hemolysis ring was produced, it was γ-hemolysis; if a green hemolysis ring was produced, it was α-hemolysis; if a transparent hemolysis ring was produced, it was β-hemolysis. The strain was repeated three times.
[0050] 2.5 Animal experiments
[0051] A total of 96 healthy one-day-old Dawu Jinfeng laying chicks were used in this study. Before the experiment, the chicks were randomly divided into 8 groups, each with 12 chicks. The blank control group was fed with a basal diet. The three Bacillus subtilis control groups were fed with a basal diet and oral administration of low-dose, medium-dose, and high-dose Bacillus subtilis suspensions, respectively. The model group was fed with a basal diet and oral administration of Escherichia coli O78 suspensions every day for three days before slaughter. The three Bacillus subtilis prevention groups were fed with a basal diet and oral administration of low-dose, medium-dose, and high-dose Bacillus subtilis suspensions, respectively. They were oral administration of Escherichia coli O78 suspensions every day for three days before slaughter.
[0052] All chicks were placed in a room, with 12 chickens in each separate cage. One week before the chickens were placed, the room and cages were disinfected according to routine procedures. The indoor temperature was controlled at 35°C, reduced by 3°C every week until 29°C, and the humidity was controlled at 50%-60%. During the feeding period, feed was added and water was changed regularly every morning and evening, and the chicken house was cleaned and disinfected regularly. When the chicks were 1-3 days old, the light cycle was 24 hours a day, with natural light during the day and ordinary fluorescent lights at night. After 3 days of age, the light cycle was controlled at 18 hours a day, with natural ventilation, autonomous feeding and free drinking water. The feeding experiment lasted a total of 4 weeks, with the first week being the adaptive feeding stage and the last three weeks being the formal experiment.
[0053] Biological sample collection: The chicks were weighed and recorded weekly, and the feed intake of each group was weighed and recorded daily. Then, the chicks were euthanized to collect tissues. Duodenal tissue was taken to make intestinal paraffin sections for HE staining. The mid-jejunal tissue was taken and placed in a sterile cryotube. DNA was extracted using a tissue DNA extraction kit, and primers for Escherichia coli O78 were designed. qPCR was performed to analyze the colonization of Escherichia coli in the intestine. Except for the samples used for analysis, the rest of the tissue samples were stored at -80°C until the next analysis.
[0054] 3. Test results
[0055] 3.1 Screening of Bacillus subtilis
[0056] Through culture medium morphological analysis combined with 16S rRNA identification, three strains of Bacillus subtilis were screened and named Bacillus subtilis JZH2, Bacillus subtilis JZH 9 and Bacillus subtilis JZH11 respectively.
[0057] Bacillus subtilis was screened through in vitro antibacterial experiments for comparison of antibacterial effects. The experimental results are shown in Table 1. Bacillus subtilis JZH 9 has a better antibacterial effect and was selected as the subsequent experimental bacteria.
[0058] Table 1 Antibacterial test results
[0059]
[0060] Note: The outer diameter of the Oxford quilt is 8mm. If the inhibition zone is less than 8mm, it has no antibacterial effect. If the inhibition zone is 8-10mm, it is relatively sensitive. If the inhibition zone is greater than 10mm, it is sensitive.
[0061] Bacillus subtilis JZH 9 was used to build a homology phylogenetic tree, such as Figure 1 shown.
[0062] The Bacillus subtilis JZH 9 was deposited in the General Microbiology Center of the China Microbiological Culture Collection Administration on May 10, 2024, with the deposit number CGMCC No. 30580. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, Tel: 010-64807355, Fax: 010-64807288, Email: cgmcc@im.ac.cn.
[0063] 3.2 Resistance test results
[0064] Acid resistance: The survival rates of Bacillus subtilis JZH 9 at pH 2.0, 3.0, 4.0, and 5.0 were 14.98%, 38.56%, 63.38%, and 85.71%, respectively. Figure 2 ).
[0065] Bile salt tolerance: Bacillus subtilis JZH 9 has bile salt tolerance. After being treated with sodium taurocholate, the growth of Bacillus subtilis did not change significantly ( Figure 3 ).
[0066] Resistance to artificial gastrointestinal fluid: After being treated with artificial gastric fluid for 2 hours, the survival rate of Bacillus subtilis JZH 9 decreased significantly, and treatment with artificial gastric fluid for 0 hours had no significant effect on the survival rate; after being treated with artificial intestinal fluid for 0 hours and 2 hours, the survival rate decreased significantly, as shown in Table 2.
[0067] Table 2 Growth of Bacillus subtilis after treatment with artificial gastrointestinal fluid for 0h and 2h
[0068]
[0069] 3.3 Hemolytic test results
[0070] The experimental results are as follows Figure 4 As shown, it can be seen that Bacillus subtilis JZH 9 has no hemolytic activity.
[0071] 3.4 In vivo experimental results
[0072] 3.4.1 Effects of Bacillus subtilis from chicken on growth performance of chicks
[0073] As shown in Table 3, there was no significant difference in the body weight of chicks among the groups on the 7th and 21st days (P>0.05); the body weight of the high-dose control group was significantly reduced on the 14th day (P=0.033); compared with the blank control group, the low-dose control group significantly reduced the feed conversion rate of the chicks on days 1-7 (P=0.015); the high-dose control group significantly reduced the average daily weight gain of the chicks on days 8-14 (P=0.009); the low-dose control group significantly reduced the average daily feed intake of the chicks on days 8-14 (P=0.04) and 15-21 (P=0.012); on days 15-21, there was no significant difference in the average daily weight gain and feed conversion rate among the groups (P>0.05).
[0074] Table 3 Effects of different concentrations of Bacillus subtilis on the growth performance of laying hens
[0075]
[0076] Note: For horizontal comparison, the differences between samples with the same letter are not significant, and the differences between samples with different letters are significant; CON: control group; LBS: low-dose Bacillus subtilis control group (1×10 9 CFU / mL; MBS: medium-dose Bacillus subtilis control group (1×10 10 CFU / mL; HBS: high-dose Bacillus subtilis control group (1×10 11 CFU / mL). ADG: average daily gain; ADFI: average daily feed intake; FCR: feed conversion ratio.
[0077] As shown in Table 4, on the 7th day, there was no significant difference in the weight of chicks among the groups (P>0.05). Compared with the model group, on the 21st day, the medium-dose group significantly reduced the weight of chicks (P=0.043); on the 15th to 21st day, compared with the control group, the model group significantly reduced the average daily weight gain (P=0.032) and average daily feed intake (P=0.012); compared with the control group, the average daily weight gain of the low-dose group was not significantly different (P=0.301), while the average daily weight gain of the medium-dose group (P=0.044) and the high-dose group (P=0.007) was significantly decreased; on the 15th to 21st day, compared with the model group, the average daily weight gain of the low-dose group, the medium-dose group, and the high-dose group was not significantly different (P>0.05), and the average daily feed intake of the medium-dose group was significantly decreased (P=0.045).
[0078] No mortality was observed during the entire experimental period.
[0079] Table 4 Effects of different concentrations of Bacillus subtilis on the growth performance of laying hens challenged with Escherichia coli
[0080]
[0081] Note: For horizontal comparison, those with the same letter are not significantly different, and those with different letters are significantly different; CON: control group; Model: model group (E. coli O78: 4.5×10 12 CFU / mL; LBS+E.coli: low-dose Bacillus subtilis group (Bacillus subtilis (1×10 9 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL)); MBS+E.coli: medium-dose Bacillus subtilis group (Bacillus subtilis (1×10 10 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL)); HBS+E.coli: high-dose Bacillus subtilis group (Bacillus subtilis (1×10 11 CFU / mL)+E. coli O78 (4.5×10 12 CFU / mL)). ADG: average daily gain; ADFI: average daily feed intake; FCR: feed conversion ratio.
[0082] 3.4.2 Effects of chicken-derived Bacillus subtilis on duodenal structure, villus height, and crypt depth in chicks
[0083] The effects of oral administration of Bacillus subtilis on the structural integrity of the duodenum, villus height, crypt depth and villus-crypt ratio of chicks for a period of time were investigated. HE staining and quantitative analysis were performed on the duodenum of chicks in each treatment group. The results of HE staining showed that the villi of the groups not treated with E. coli O78 (blank control group, low-dose Bacillus subtilis control group, medium-dose Bacillus subtilis control group, and high-dose Bacillus subtilis control group) were finger-like protrusions, the intestinal villi were arranged relatively tightly and neatly, the crypts were clearly visible, and the tissue structure was intact ( Figure 5 ); The height of the villi increased in both the medium-dose and high-dose control groups, and the height of the villi increased significantly in the high-dose control group (Table 5). The villi structure was destroyed and truncated in the E. coli O78-treated groups (model group, low-dose Bacillus subtilis group, medium-dose Bacillus subtilis group, and high-dose Bacillus subtilis group), and part of the villi structure was missing ( Figure 5 ); Compared with the control group, the model group significantly reduced the height of the villi and increased the depth of the crypts; compared with the model group, the low, medium and high dose groups all significantly increased the height of the villi and the villus-crypt ratio, and the medium and high dose groups significantly reduced the depth of the crypts (Table 5). The results showed that Bacillus subtilis can increase the height of the villi and the villus-crypt ratio of the duodenum, improve the intestinal structure, enhance the intestinal barrier function, and alleviate the damage of Escherichia coli O78 to the intestine.
[0084] Table 5 Villus height, crypt depth and villus-crypt ratio of the duodenum of chicks in each treatment group
[0085]
[0086] Note: For longitudinal comparison, those with the same letter have no significant difference, and those with different letters have significant difference; Villus height: villus height; Crypt depth: crypt depth; Villus-crypt ratio: villus-crypt ratio.
[0087] 3.4.3 Effect of Bacillus subtilis on intestinal colonization of Escherichia coli O78
[0088] Bacillus subtilis can significantly improve the colonization of Escherichia coli O78 in the intestine. Compared with the CON group, the Escherichia coli content in the Model group was significantly increased, while the low, medium and high doses of Bacillus subtilis taken orally in advance significantly reduced the content of Escherichia coli in the jejunum ( Figure 6 ).
[0089] Bacillus subtilis can prevent diarrhea in chicks caused by E. coli O78. The bacteria has a certain tolerance to bile salts. When the pH is 3-4, the survival rate reaches 38.56%-63.38%, which enables it to colonize in the intestine through the gastrointestinal environment. The bacteria can increase the height of the intestinal villi and the villus-crypt ratio, improve the intestinal structure, and reduce the content of E. coli in the intestine, reducing the colonization of E. coli O78 in the intestine. Thus, it can protect the body.
[0090] The invention provides a strain of Bacillus subtilis JZH 9 capable of inhibiting Escherichia coli. The Bacillus subtilis JZH 9 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration on May 10, 2024, with a deposit number of CGMCC No. 30580. The Bacillus subtilis JZH 9 can prevent diarrhea in chicks caused by Escherichia coli O78; it has a certain tolerance to bile salts, and when the pH is 3-4, the survival rate reaches 38.56%-63.38%, so that it can colonize in the intestine through the gastrointestinal environment. Bacillus subtilis JZH 9 can increase the height of intestinal tissue villi and the villus-cryptographic ratio, improve the intestinal structure, and can reduce the content of intestinal Escherichia coli, reduce the colonization of Escherichia coli O78 in the intestine, thereby achieving a protective effect on the body.
Claims
1. A strain of Bacillus subtilis JZH 9 capable of inhibiting Escherichia coli, characterized in that: The Bacillus subtilis JZH 9 was deposited in the General Microbiology Center of the China Microorganism Culture Collection Administration on May 10, 2024, with the deposit number CGMCC No.30580.
2. Use of the Bacillus subtilis JZH 9 as claimed in claim 1 in inhibiting the growth of Escherichia coli.
3. Use of Bacillus subtilis JZH 9 as claimed in claim 1 in promoting the growth of chicks.
4. Use of the Bacillus subtilis JZH 9 as claimed in claim 1 in increasing the villus height and villus-to-crypt ratio of the duodenum.
5. Use of the Bacillus subtilis JZH 9 according to claim 1 in improving intestinal structure and enhancing intestinal barrier function.
6. Use of the Bacillus subtilis JZH 9 according to claim 1 in reducing intestinal colonization of Escherichia coli.
7. A bacterial agent, characterized in that: The bacterial agent is prepared by fermenting the Bacillus subtilis JZH 9 strain according to claim 1.
8. A feed additive, characterized in that: The feed additive comprises the bacterial agent according to claim 1 and other nutrients acceptable to the feed.
9. The feed additive according to claim 8, characterized in that The other nutrients include at least one of probiotics, minerals and vitamins.
